Treating symptomatic hyperprolactinemia in women with schizophrenia: Presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin)

Deanna L. Kelly, Heidi J. Wehring, Amber K. Earl, Kelli M. Sullivan, Faith B. Dickerson, Stephanie Feldman, Robert P. McMahon, Robert W. Buchanan, Dale Warfel, William R. Keller, Bernard A. Fischer, Joo Cheol Shim

Research output: Contribution to journalArticlepeer-review

Abstract

Prolactin elevations occur in people treated with antipsychotic medications and are often much higher in women than in men. Hyperprolactinemia is known to cause amenorrhea, oligomenorrhea, galactorrhea and gynecomastia in females and is also associated with sexual dysfunction and bone loss. These side effects increase risk of antipsychotic nonadherence and suicide and pose significant problems in the long term management of women with schizophrenia. In this manuscript, we review the literature on prolactin; its physiology, plasma levels, side effects and strategies for treatment. We also present the rationale and protocol for an ongoing clinical trial to treat symptomatic hyperprolactinemia in premenopausal women with schizophrenia. More attention and focus are needed to address these significant side effects and help the field better personalize the treatment of women with schizophrenia.

Original languageEnglish (US)
Article number214
JournalBMC Psychiatry
Volume13
DOIs
StatePublished - Aug 22 2013
Externally publishedYes

Keywords

  • Amenorrhea
  • Aripiprazole
  • Clinical trial
  • Galactorrhea
  • Osteoporosis
  • Prolactin
  • Sexual dysfunction
  • Women

ASJC Scopus subject areas

  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Treating symptomatic hyperprolactinemia in women with schizophrenia: Presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin)'. Together they form a unique fingerprint.

Cite this